CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 48 enrolled
Drug / intervention
Tranexamic acid injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05024253
NCT05024253Phase 3Completed
CompareCT.gov

Does Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Reduce Blood Loss and Transfusion Requirements? A Double-blinded Randomized Controlled Trial

Children's Cancer Hospital Egypt 57357·interventional·Posted Aug 27, 2021·Updated Feb 7, 2024

In Brief

A Phase 3 clinical trial evaluating Tranexamic acid injection and Saline for Ewing Sarcoma of Bone and Osteosarcoma. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The purpose of this trial is to investigate whether previously reported benefit of Tranexamic acid in pediatric orthopedic surgeries could be recapitulated in bone tumor surgeries or not through a double blinded randomized controlled trial done in children cancer hospital 57357.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEwing Sarcoma of Bone, Osteosarcoma
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedAug 27, 2021
Enrollment StartAug 2, 2021
Primary CompletionFeb 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.8 years ago

Interventions

Tranexamic acid injectiondrug

. TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)

Salineother

mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl